Francesco Passamonti, MD, University of Insubria, Varese, Italy, briefly discusses the current state-of-the-art in polycythemia vera (PV), highlighting the value of agents including ropeginterferon alfa-2b and ruxolitinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.